Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer
To explore whether preoperative chemoradiation therapy improves survival of patients with pancreatic cancer undergoing resectional surgery. Forty-seven patients with a malignant pancreatic tumor localized in the head or uncinate process of the pancreas underwent radical pancreatico-duodenectomy. Twe...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2007-06, Vol.13 (21), p.2945-2951 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2951 |
|---|---|
| container_issue | 21 |
| container_start_page | 2945 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 13 |
| creator | Vento, Pälvi Mustonen, Harri Joensuu, Timo Kärkkäinen, Päivi Kivilaakso, Eero Kiviluoto, Tuula |
| description | To explore whether preoperative chemoradiation therapy improves survival of patients with pancreatic cancer undergoing resectional surgery.
Forty-seven patients with a malignant pancreatic tumor localized in the head or uncinate process of the pancreas underwent radical pancreatico-duodenectomy. Twenty-two received chemoradiation therapy (gemcitabine and radiation dose 50.4 Gy) before surgery (CRR) and 25 patients underwent surgery only (RO). The study was non-randomised. Patients were identified from a prospective database.
The median survival time was 30.2 mo in the CRR group and 35.9 mo in the RO group. No statistically significant differences were found in subclasses according to lymph node involvement, TNM stages, tumor size, or perineural invasion. The one, three and five year survival rates were 81%, 33% and 33%, respectively, in the CRR group and 72%, 47% and 23%, respectively, in the RO group. In ductal adenocarcinoma, the median survival time was 27 mo in the CRR group and 20 mo in the RO group. No statistically significant differences were found in the above subclasses. The one, three and five year survival rates were 79%, 21% and 21%, respectively, in the CRR group and 64%, 50% and 14%, respectively, in the RO group. The overall hospital mortality rate was 2%. The morbidity rate was 45% in the CRR group and 32% (NS) in the RO group.
Major multicenter randomized studies are needed to conclusively assess the impact of neoadjuvant treatment in the management of pancreatic cancer. |
| doi_str_mv | 10.3748/wjg.v13.i21.2945 |
| format | Article |
| fullrecord | <record><control><sourceid>wanfang_jour_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4171146</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><wanfj_id>wjg200721007</wanfj_id><sourcerecordid>wjg200721007</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-429f42d2a05983b7b5611cee3e53c69c4603057863d3d4a7eb22730a0fa2b8e83</originalsourceid><addsrcrecordid>eNpVUctqwzAQFKWlSdPeeyo69OpUWsmWfSmU0kcg0Et7FrK8ThQSy8iOQ_6-Cgl9nFbszI6GGUJuOZsKJfOH3WoxHbiYOuBTKGR6RsYAvEggl-ycjDljKikEqBG56roVYyBECpdkxFWaF4WUY1LONq2xPfU1bQP6FoPp3YDULnHjg6mc75dx1-6pb2i3DYMbzJq6hraRh03f0Z3rlzRgh7Y35Roj0NiAEbXUxieGa3JRm3WHN6c5IV-vL5_P78n84232_DRPrATRJxKKWkIFhqVFLkpVphnnFlFgKmxWWJkxwVKVZ6ISlTQKSwAlmGG1gTLHXEzI41G33ZYbrGx0F8xat8FtTNhrb5z-jzRuqRd-0JIrzmUWBe6PAjvT1KZZ6JXfhiZa1jFniFnCIdBIY0eaDb7rAtY_X3CmD7Uc6DrWomMt-lBLPLn7a-334NSD-AaXpoyV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Vento, Pälvi ; Mustonen, Harri ; Joensuu, Timo ; Kärkkäinen, Päivi ; Kivilaakso, Eero ; Kiviluoto, Tuula</creator><creatorcontrib>Vento, Pälvi ; Mustonen, Harri ; Joensuu, Timo ; Kärkkäinen, Päivi ; Kivilaakso, Eero ; Kiviluoto, Tuula</creatorcontrib><description>To explore whether preoperative chemoradiation therapy improves survival of patients with pancreatic cancer undergoing resectional surgery.
Forty-seven patients with a malignant pancreatic tumor localized in the head or uncinate process of the pancreas underwent radical pancreatico-duodenectomy. Twenty-two received chemoradiation therapy (gemcitabine and radiation dose 50.4 Gy) before surgery (CRR) and 25 patients underwent surgery only (RO). The study was non-randomised. Patients were identified from a prospective database.
The median survival time was 30.2 mo in the CRR group and 35.9 mo in the RO group. No statistically significant differences were found in subclasses according to lymph node involvement, TNM stages, tumor size, or perineural invasion. The one, three and five year survival rates were 81%, 33% and 33%, respectively, in the CRR group and 72%, 47% and 23%, respectively, in the RO group. In ductal adenocarcinoma, the median survival time was 27 mo in the CRR group and 20 mo in the RO group. No statistically significant differences were found in the above subclasses. The one, three and five year survival rates were 79%, 21% and 21%, respectively, in the CRR group and 64%, 50% and 14%, respectively, in the RO group. The overall hospital mortality rate was 2%. The morbidity rate was 45% in the CRR group and 32% (NS) in the RO group.
Major multicenter randomized studies are needed to conclusively assess the impact of neoadjuvant treatment in the management of pancreatic cancer.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v13.i21.2945</identifier><identifier>PMID: 17589944</identifier><language>eng</language><publisher>United States: Departments of Surgery, Helsinki University Central Hospital,Helsinki, Finland%Departments of Oncology, Helsinki University Central Hospital, Helsinki, Finland%Departments of Pathology, Helsinki University Central Hospital, Helsinki, Finland</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - radiotherapy ; Adenocarcinoma - surgery ; Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic - therapeutic use ; Chemotherapy, Adjuvant ; Clinical Research ; Combined Modality Therapy ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Dose-Response Relationship, Radiation ; Female ; Hospital Mortality ; Humans ; Male ; Middle Aged ; Neoadjuvant Therapy ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - radiotherapy ; Pancreatic Neoplasms - surgery ; Pancreaticoduodenectomy ; Radiotherapy, Adjuvant ; Survival Rate</subject><ispartof>World journal of gastroenterology : WJG, 2007-06, Vol.13 (21), p.2945-2951</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><rights>2007 Baishideng Publishing Group Co., Limited. All rights reserved. 2007</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-429f42d2a05983b7b5611cee3e53c69c4603057863d3d4a7eb22730a0fa2b8e83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.wanfangdata.com.cn/images/PeriodicalImages/wjg/wjg.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171146/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171146/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17589944$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vento, Pälvi</creatorcontrib><creatorcontrib>Mustonen, Harri</creatorcontrib><creatorcontrib>Joensuu, Timo</creatorcontrib><creatorcontrib>Kärkkäinen, Päivi</creatorcontrib><creatorcontrib>Kivilaakso, Eero</creatorcontrib><creatorcontrib>Kiviluoto, Tuula</creatorcontrib><title>Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer</title><title>World journal of gastroenterology : WJG</title><addtitle>World J Gastroenterol</addtitle><description>To explore whether preoperative chemoradiation therapy improves survival of patients with pancreatic cancer undergoing resectional surgery.
Forty-seven patients with a malignant pancreatic tumor localized in the head or uncinate process of the pancreas underwent radical pancreatico-duodenectomy. Twenty-two received chemoradiation therapy (gemcitabine and radiation dose 50.4 Gy) before surgery (CRR) and 25 patients underwent surgery only (RO). The study was non-randomised. Patients were identified from a prospective database.
The median survival time was 30.2 mo in the CRR group and 35.9 mo in the RO group. No statistically significant differences were found in subclasses according to lymph node involvement, TNM stages, tumor size, or perineural invasion. The one, three and five year survival rates were 81%, 33% and 33%, respectively, in the CRR group and 72%, 47% and 23%, respectively, in the RO group. In ductal adenocarcinoma, the median survival time was 27 mo in the CRR group and 20 mo in the RO group. No statistically significant differences were found in the above subclasses. The one, three and five year survival rates were 79%, 21% and 21%, respectively, in the CRR group and 64%, 50% and 14%, respectively, in the RO group. The overall hospital mortality rate was 2%. The morbidity rate was 45% in the CRR group and 32% (NS) in the RO group.
Major multicenter randomized studies are needed to conclusively assess the impact of neoadjuvant treatment in the management of pancreatic cancer.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - radiotherapy</subject><subject>Adenocarcinoma - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical Research</subject><subject>Combined Modality Therapy</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Dose-Response Relationship, Radiation</subject><subject>Female</subject><subject>Hospital Mortality</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - radiotherapy</subject><subject>Pancreatic Neoplasms - surgery</subject><subject>Pancreaticoduodenectomy</subject><subject>Radiotherapy, Adjuvant</subject><subject>Survival Rate</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUctqwzAQFKWlSdPeeyo69OpUWsmWfSmU0kcg0Et7FrK8ThQSy8iOQ_6-Cgl9nFbszI6GGUJuOZsKJfOH3WoxHbiYOuBTKGR6RsYAvEggl-ycjDljKikEqBG56roVYyBECpdkxFWaF4WUY1LONq2xPfU1bQP6FoPp3YDULnHjg6mc75dx1-6pb2i3DYMbzJq6hraRh03f0Z3rlzRgh7Y35Roj0NiAEbXUxieGa3JRm3WHN6c5IV-vL5_P78n84232_DRPrATRJxKKWkIFhqVFLkpVphnnFlFgKmxWWJkxwVKVZ6ISlTQKSwAlmGG1gTLHXEzI41G33ZYbrGx0F8xat8FtTNhrb5z-jzRuqRd-0JIrzmUWBe6PAjvT1KZZ6JXfhiZa1jFniFnCIdBIY0eaDb7rAtY_X3CmD7Uc6DrWomMt-lBLPLn7a-334NSD-AaXpoyV</recordid><startdate>20070607</startdate><enddate>20070607</enddate><creator>Vento, Pälvi</creator><creator>Mustonen, Harri</creator><creator>Joensuu, Timo</creator><creator>Kärkkäinen, Päivi</creator><creator>Kivilaakso, Eero</creator><creator>Kiviluoto, Tuula</creator><general>Departments of Surgery, Helsinki University Central Hospital,Helsinki, Finland%Departments of Oncology, Helsinki University Central Hospital, Helsinki, Finland%Departments of Pathology, Helsinki University Central Hospital, Helsinki, Finland</general><general>Baishideng Publishing Group Co., Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope><scope>5PM</scope></search><sort><creationdate>20070607</creationdate><title>Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer</title><author>Vento, Pälvi ; Mustonen, Harri ; Joensuu, Timo ; Kärkkäinen, Päivi ; Kivilaakso, Eero ; Kiviluoto, Tuula</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-429f42d2a05983b7b5611cee3e53c69c4603057863d3d4a7eb22730a0fa2b8e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - radiotherapy</topic><topic>Adenocarcinoma - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical Research</topic><topic>Combined Modality Therapy</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Dose-Response Relationship, Radiation</topic><topic>Female</topic><topic>Hospital Mortality</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - radiotherapy</topic><topic>Pancreatic Neoplasms - surgery</topic><topic>Pancreaticoduodenectomy</topic><topic>Radiotherapy, Adjuvant</topic><topic>Survival Rate</topic><toplevel>online_resources</toplevel><creatorcontrib>Vento, Pälvi</creatorcontrib><creatorcontrib>Mustonen, Harri</creatorcontrib><creatorcontrib>Joensuu, Timo</creatorcontrib><creatorcontrib>Kärkkäinen, Päivi</creatorcontrib><creatorcontrib>Kivilaakso, Eero</creatorcontrib><creatorcontrib>Kiviluoto, Tuula</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vento, Pälvi</au><au>Mustonen, Harri</au><au>Joensuu, Timo</au><au>Kärkkäinen, Päivi</au><au>Kivilaakso, Eero</au><au>Kiviluoto, Tuula</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World J Gastroenterol</addtitle><date>2007-06-07</date><risdate>2007</risdate><volume>13</volume><issue>21</issue><spage>2945</spage><epage>2951</epage><pages>2945-2951</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>To explore whether preoperative chemoradiation therapy improves survival of patients with pancreatic cancer undergoing resectional surgery.
Forty-seven patients with a malignant pancreatic tumor localized in the head or uncinate process of the pancreas underwent radical pancreatico-duodenectomy. Twenty-two received chemoradiation therapy (gemcitabine and radiation dose 50.4 Gy) before surgery (CRR) and 25 patients underwent surgery only (RO). The study was non-randomised. Patients were identified from a prospective database.
The median survival time was 30.2 mo in the CRR group and 35.9 mo in the RO group. No statistically significant differences were found in subclasses according to lymph node involvement, TNM stages, tumor size, or perineural invasion. The one, three and five year survival rates were 81%, 33% and 33%, respectively, in the CRR group and 72%, 47% and 23%, respectively, in the RO group. In ductal adenocarcinoma, the median survival time was 27 mo in the CRR group and 20 mo in the RO group. No statistically significant differences were found in the above subclasses. The one, three and five year survival rates were 79%, 21% and 21%, respectively, in the CRR group and 64%, 50% and 14%, respectively, in the RO group. The overall hospital mortality rate was 2%. The morbidity rate was 45% in the CRR group and 32% (NS) in the RO group.
Major multicenter randomized studies are needed to conclusively assess the impact of neoadjuvant treatment in the management of pancreatic cancer.</abstract><cop>United States</cop><pub>Departments of Surgery, Helsinki University Central Hospital,Helsinki, Finland%Departments of Oncology, Helsinki University Central Hospital, Helsinki, Finland%Departments of Pathology, Helsinki University Central Hospital, Helsinki, Finland</pub><pmid>17589944</pmid><doi>10.3748/wjg.v13.i21.2945</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2007-06, Vol.13 (21), p.2945-2951 |
| issn | 1007-9327 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4171146 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - radiotherapy Adenocarcinoma - surgery Adult Aged Aged, 80 and over Antimetabolites, Antineoplastic - therapeutic use Chemotherapy, Adjuvant Clinical Research Combined Modality Therapy Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Dose-Response Relationship, Radiation Female Hospital Mortality Humans Male Middle Aged Neoadjuvant Therapy Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - radiotherapy Pancreatic Neoplasms - surgery Pancreaticoduodenectomy Radiotherapy, Adjuvant Survival Rate |
| title | Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T15%3A14%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20preoperative%20chemoradiotherapy%20on%20survival%20in%20patients%20with%20resectable%20pancreatic%20cancer&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Vento,%20P%C3%A4lvi&rft.date=2007-06-07&rft.volume=13&rft.issue=21&rft.spage=2945&rft.epage=2951&rft.pages=2945-2951&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v13.i21.2945&rft_dat=%3Cwanfang_jour_pubme%3Ewjg200721007%3C/wanfang_jour_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17589944&rft_wanfj_id=wjg200721007&rfr_iscdi=true |